The mission of the Gene Expression and Genotyping Facility (GEGF) is to facilitate implementation of highthroughput genetic technologies for the research conducted by members of the Case community. The GEGFserves as a technical and consulting resource for Cancer Center members, as well as other investigators whohave laboratories at Case Western Reserve University, University Hospitals of Cleveland, the Cleveland ClinicFoundation, the VA Hospital, and MetroHealth Hospital in the areas of high throughput expression analysis andgenotyping. It is the only facility of its capability in Cleveland. This facility utilizes Affymetrix and AppliedBiosystems (ABI) technologies to provide global and quantitative (on user-identified genes) gene expressionanalysis services. A diverse array of Affymetrix and ABI technologies are available to address a spectrum ofgenotyping needs, including whole genome scans, custom designed fine-mapping studies involving 3,000-10,000SNPs and interrogation of small numbers (<100) of specific SNPs in thousands of samples. The core operates ina full-service mode with staff providing initial consultation, executing the chemistry, carrying out the analysis, andoffering data trimming and data interpretation services. To carry out these technologies, the GEGF has 14computers, an Affymetrix Workstation dedicated to data generation, 3 fluidics stations, 2 hybridization ovens anda GC3000 scanner with autoloader. ABI equipment includes a 7,900 Sequence Detection System, with a barcodereader, robotics allowing the capability to process 5,000 sample wells per day, and the modules for processingLow Density Arrays, 96- and 384-well plates. The GEGF also has 5 GeneAMP ABI 9700 PCR machines, with 96-& 384-well block capability and an ABI 6100 Nucleic Acid Prep Station. For PCR-based assays, the GEGFestablished an amplicon-free room, containing 2 PCR hoods, dedicated pipettors, small microfuges and minithermocyclers.Additional equipment includes: 2 Matrix robotic liquid handling systems, the PlateMate 2x2 (X-Ystage movement) and the PlateMate Plus (allows rapid reconfiguration from 96- to 384-well format), dedicatedcentrifuges, an Agilent Bioanalyzer and a NanoDrop Spectrophotometer, which quantifies nucleic acids in 1-2 ulsamples. Turn-around time for sample preparation and analysis is <10 days for average size projects andsatisfactory timetables are established for large projects during initial consultations. Cancer Center membersreceive a 35% discount on all GEGF provided services. The core has steadily grown from its inception in 2000,when we had 22 users and a single full-time staff member to its current staff of 51/2 and 142 registered users.Approximately 60 investigators use the GEGF every year and 30-50% of these are first time users, documentingthat the GEGF continues to enjoy a healthy level of growth and a robust level of sustained work with repeat users.Finally, the GEGF has provided services for members from 8 of the Cancer Center's programs, and has played arole in securing more than 33 grants awarded to Cancer Center members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA043703-18
Application #
7529366
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-07-06
Project End
2012-03-31
Budget Start
2007-07-06
Budget End
2008-03-31
Support Year
18
Fiscal Year
2007
Total Cost
$225,435
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279
Benson, Bryan L; Li, Lucy; Myers, Jay T et al. (2018) Biomimetic post-capillary venule expansions for leukocyte adhesion studies. Sci Rep 8:9328
Bosca, Federica; Bielecki, Peter A; Exner, Agata A et al. (2018) Porphyrin-Loaded Pluronic Nanobubbles: A New US-Activated Agent for Future Theranostic Applications. Bioconjug Chem 29:234-240
Cooper, Gregory S; Markowitz, Sanford D; Chen, Zhengyi et al. (2018) Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing. Dig Dis Sci 63:1449-1453
Morrow, James J; Bayles, Ian; Funnell, Alister P W et al. (2018) Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med 24:176-185
Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182
Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266
Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:
Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151

Showing the most recent 10 out of 1227 publications